Multidisciplinary Cutaneous Lymphoma Group

Clinical Trials

There are many therapy choices for CTCL (MF/SS) and other cutaneous lymphomas, however none of the currently available therapies have resulted in reliable long-term response or curative results.  Also, there are significant toxicities associated with many of the therapies used for patients with advanced disease.  Thus, newer therapies that are more effective and safe are greatly in need.  In recent years, our cutaneous lymphoma group has been involved in taking a leadership role in the research and development of new therapies in cutaneous lymphoma, whether it isin designing and leading single or multicenter new therapy trials or as part of collaborative translational research at Stanford.


A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

The purpose of this trial is to assess the efficacy and safety of E7777 (improved purity ONTAK [denileukin diftitox]) in patients with persistent and recurrent cutaneous T-cell lymphoma. A Lead-in dose-finding part will be used to determine the dose of E7777 that should be used to test efficacy and safety. More »


Pilot Study of Brentuximab Vedotin (SGN-35) in Patients with MF with Variable CD30 Expression Level

The purpose of this study is to learn the effects of an investigational medication, SGN 35, on patients with mycosis fungoides. This investigational drug may offer less toxicity than standard treatments and have better tumor specific targeting. The primary objective is to explore the biologic activity of brentuximab vedotin (SGN-35) in patients with mycosis fungoides (MF) and Sézary syndrome (SS), the most common group of cutaneous T-cell lymphoma (CTCL), where expression of CD30 is variable. More »


Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

The purpose of this study is to investigate the safety and tolerability of topical SHP141 applied directly to skin lesions in patients with Stage IA, IB, or IIA Cutaneous T-cell Lymphoma. This study will also investigate the effect of SHP141 on skin lesions in patients with Stage IA, IB, or IIA CTCL. More »


Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing

The goal of this study is to identify genetic changes associated with the initiation, progression, and treatment response of response of cutaneous and hematologic disorders using recently developed high-throughput sequencing technologies. The improved understanding of the genetic changes associated with cutaneous and hematologic disorders may lead to improved diagnostic, prognostic and therapeutic options for these disorders.
More »


Low-dose (12 Gy) TSEBT+ Vorinostat VS Low-dose TSEBT Monotherapy in Mycosis Fungoides

The purpose of this study is to determine if vorinostat combined with low-dose total skin electron beam therapy (TSEBT) offers superior clinical benefit (efficacy & safety) over low-dose TSEBT alone. More »


A Phase 3 Trial of Brentuximab Vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients with CD30-Positive Cutaneous T-Cell Lymphoma

This is a Randomized, Open-Label, Phase 3 trial of brentuximab vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma. More »


Study of KW-0761 Versus Vorinostat in Relapsed/Refactory CTCL

The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL. More »


Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG in Patients w/Cutaneous T-Cell Lymphoma

Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given that the median age at diagnosis is 55-60 years and frequently present compromised skin in these patients, which increases the risk of infection. Therefore, we propose a clinical study with allogeneic HSCT using a unique non-myeloablative preparative regimen, TLI/ATG, to treat advanced MF/SS. More »


Stanford Medicine Resources:

Footer Links: